HDS: Establishment of a new cell line from a hairy cell leukemia patient with resistance to alpha-interferon therapy

Suresh Vedantham; Shi Hua Wu; Dorit Gurfel; Rosa Lovis; Harvey M. Golomb; Haim Gamliel

doi:10.3109/10428199109067636

HDS: Establishment of a new cell line from a hairy cell leukemia patient with resistance to alpha-interferon therapy

Suresh Vedantham, Shi Hua Wu, Dorit Gurfel, Rosa Lovis, Harvey M. Golomb, Haim Gamliel

Research output: Contribution to journal › Article › peer-review

Abstract

A new cell line, designated "HDS" was established in a suspension culture derived from the peripheral blood of a patient with hairy cell leukemia (HCL) who developed clinical resistance to alpha-interferon (aIFN) therapy. The patient exhibited a clinical picture characteristic of HCL, including splenomegaly, cytopenias, and tartrate-resistant acid phosphatase (TRAP)-positive "hairy" cells in blood and marrow. Chromosomal studies revealed that the cultured cells possess the chromosomal abnormality +12. Cytochemical and immunologic studies show the HDS cell line had the phenotype of a B-lymphocyte. HDS cells expressed the HLA-DR and CD19 surface antigens, but were negative for early B (CD10) and T (CD2, CD3) cell markers. The cells are also negative for other T-cell, granulocytic and monocytic markers and for typical HCL markers such as CD11c and CD22. However, the expression of these antigens was induced by in-vitro treatment of the cells with the differentiation-inducing agent tetradecanoyl phorbol acetate (TPA). Ultrastructural analyses of the cultured cells revealed a display of surface microvilli mixed with ruffles in a classical hairy cell pattern. It is therefore highly likely that the HDS cells represent HCL cells in an atypical stage of differentiation.

Original language	English
Pages (from-to)	407-413
Number of pages	7
Journal	Leukemia and Lymphoma
Volume	5
Issue number	5-6
DOIs	https://doi.org/10.3109/10428199109067636
State	Published - 1991

Keywords

Cell line
Drug resistance
Hairy cell
Immunolabeling
Interferon
Leukemia
TPA

Access to Document

10.3109/10428199109067636

Cite this

@article{97ac4cf15ce8414dbfa0c4c7d48d3d0d,

title = "HDS: Establishment of a new cell line from a hairy cell leukemia patient with resistance to alpha-interferon therapy",

abstract = "A new cell line, designated {"}HDS{"} was established in a suspension culture derived from the peripheral blood of a patient with hairy cell leukemia (HCL) who developed clinical resistance to alpha-interferon (aIFN) therapy. The patient exhibited a clinical picture characteristic of HCL, including splenomegaly, cytopenias, and tartrate-resistant acid phosphatase (TRAP)-positive {"}hairy{"} cells in blood and marrow. Chromosomal studies revealed that the cultured cells possess the chromosomal abnormality +12. Cytochemical and immunologic studies show the HDS cell line had the phenotype of a B-lymphocyte. HDS cells expressed the HLA-DR and CD19 surface antigens, but were negative for early B (CD10) and T (CD2, CD3) cell markers. The cells are also negative for other T-cell, granulocytic and monocytic markers and for typical HCL markers such as CD11c and CD22. However, the expression of these antigens was induced by in-vitro treatment of the cells with the differentiation-inducing agent tetradecanoyl phorbol acetate (TPA). Ultrastructural analyses of the cultured cells revealed a display of surface microvilli mixed with ruffles in a classical hairy cell pattern. It is therefore highly likely that the HDS cells represent HCL cells in an atypical stage of differentiation.",

keywords = "Cell line, Drug resistance, Hairy cell, Immunolabeling, Interferon, Leukemia, TPA",

author = "Suresh Vedantham and Wu, {Shi Hua} and Dorit Gurfel and Rosa Lovis and Golomb, {Harvey M.} and Haim Gamliel",

note = "Funding Information: This work was supported in part by the Hematologic Research Foundation (HG), Hairy Cell Leukemia Research Foundation (HG), The Harry Greenberg Foundation (HMG), and The Schering Corporation (HMG). We thank Drs. M. Le Beau and J. Vardiman for their help in karyotyping and phenotyping the cells.",

year = "1991",

doi = "10.3109/10428199109067636",

language = "English",

volume = "5",

pages = "407--413",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "5-6",

}

TY - JOUR

T1 - HDS

T2 - Establishment of a new cell line from a hairy cell leukemia patient with resistance to alpha-interferon therapy

AU - Vedantham, Suresh

AU - Wu, Shi Hua

AU - Gurfel, Dorit

AU - Lovis, Rosa

AU - Golomb, Harvey M.

AU - Gamliel, Haim

N1 - Funding Information: This work was supported in part by the Hematologic Research Foundation (HG), Hairy Cell Leukemia Research Foundation (HG), The Harry Greenberg Foundation (HMG), and The Schering Corporation (HMG). We thank Drs. M. Le Beau and J. Vardiman for their help in karyotyping and phenotyping the cells.

PY - 1991

Y1 - 1991

N2 - A new cell line, designated "HDS" was established in a suspension culture derived from the peripheral blood of a patient with hairy cell leukemia (HCL) who developed clinical resistance to alpha-interferon (aIFN) therapy. The patient exhibited a clinical picture characteristic of HCL, including splenomegaly, cytopenias, and tartrate-resistant acid phosphatase (TRAP)-positive "hairy" cells in blood and marrow. Chromosomal studies revealed that the cultured cells possess the chromosomal abnormality +12. Cytochemical and immunologic studies show the HDS cell line had the phenotype of a B-lymphocyte. HDS cells expressed the HLA-DR and CD19 surface antigens, but were negative for early B (CD10) and T (CD2, CD3) cell markers. The cells are also negative for other T-cell, granulocytic and monocytic markers and for typical HCL markers such as CD11c and CD22. However, the expression of these antigens was induced by in-vitro treatment of the cells with the differentiation-inducing agent tetradecanoyl phorbol acetate (TPA). Ultrastructural analyses of the cultured cells revealed a display of surface microvilli mixed with ruffles in a classical hairy cell pattern. It is therefore highly likely that the HDS cells represent HCL cells in an atypical stage of differentiation.

AB - A new cell line, designated "HDS" was established in a suspension culture derived from the peripheral blood of a patient with hairy cell leukemia (HCL) who developed clinical resistance to alpha-interferon (aIFN) therapy. The patient exhibited a clinical picture characteristic of HCL, including splenomegaly, cytopenias, and tartrate-resistant acid phosphatase (TRAP)-positive "hairy" cells in blood and marrow. Chromosomal studies revealed that the cultured cells possess the chromosomal abnormality +12. Cytochemical and immunologic studies show the HDS cell line had the phenotype of a B-lymphocyte. HDS cells expressed the HLA-DR and CD19 surface antigens, but were negative for early B (CD10) and T (CD2, CD3) cell markers. The cells are also negative for other T-cell, granulocytic and monocytic markers and for typical HCL markers such as CD11c and CD22. However, the expression of these antigens was induced by in-vitro treatment of the cells with the differentiation-inducing agent tetradecanoyl phorbol acetate (TPA). Ultrastructural analyses of the cultured cells revealed a display of surface microvilli mixed with ruffles in a classical hairy cell pattern. It is therefore highly likely that the HDS cells represent HCL cells in an atypical stage of differentiation.

KW - Cell line

KW - Drug resistance

KW - Hairy cell

KW - Immunolabeling

KW - Interferon

KW - Leukemia

KW - TPA

UR - http://www.scopus.com/inward/record.url?scp=0026347981&partnerID=8YFLogxK

U2 - 10.3109/10428199109067636

DO - 10.3109/10428199109067636

M3 - Article

AN - SCOPUS:0026347981

SN - 1042-8194

VL - 5

SP - 407

EP - 413

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 5-6

ER -

HDS: Establishment of a new cell line from a hairy cell leukemia patient with resistance to alpha-interferon therapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this